Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

go back to reference Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G (2017) PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 9:499–506CrossRef Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G (2017) PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 9:499–506CrossRef

go back to reference Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR (2016) 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thoracic Oncol 11:S115CrossRef Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR (2016) 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thoracic Oncol 11:S115CrossRef

go back to reference Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC (2019) Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open 4:e000498CrossRef Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC (2019) Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open 4:e000498CrossRef

go back to reference Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRef Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRef

go back to reference Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRef Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRef

go back to reference Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C (2017) Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 12:563–569CrossRef Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C (2017) Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 12:563–569CrossRef

go back to reference Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet 387:1837–1846CrossRef Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet 387:1837–1846CrossRef

go back to reference Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M (2016) EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585–4593CrossRef Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M (2016) EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585–4593CrossRef

go back to reference Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028CrossRef Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028CrossRef

go back to reference Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387:1540–1550CrossRef Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387:1540–1550CrossRef

go back to reference Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567CrossRef Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567CrossRef

go back to reference Kaira K, Kagamu H (2019) Drastic response of re-challenge of EGFR-TKIs immediately after nivolumab therapy in EGFR-TKI-resistant patients. J Thorac Oncol 14:e135–e136CrossRef Kaira K, Kagamu H (2019) Drastic response of re-challenge of EGFR-TKIs immediately after nivolumab therapy in EGFR-TKI-resistant patients. J Thorac Oncol 14:e135–e136CrossRef

go back to reference Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC (2018) Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA oncology 4:210–216CrossRef Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC (2018) Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA oncology 4:210–216CrossRef

go back to reference Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB (2018) A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 13:1138–1145CrossRef Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB (2018) A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 13:1138–1145CrossRef

go back to reference Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, Adamchuk G, Ahn M-J, Alexandru A, Altundag O, Alyasova A, Andrusenko O, Aoe K, Araujo A, Aren O, Arrieta Rodriguez O, Ativitavas T, Avendano O, Barata F, Barrios CH, Beato C, Bergstrom P, Betticher D, Bolotina L, Bondarenko I, Botha M, Buddu S, Caglevic C, Cardona A, Castro G, Castro H, Cay Senler F, Cerny CAS, Cesas A, Chan G-C, Chang J, Chen G, Chen X, Cheng S, Cheng Y, Cherciu N, Chiu C-H, Cho BC, Cicenas S, Ciurescu D, Cohen G, Costa MA, Danchaivijitr P, De Angelis F, de Azevedo SJ, Dediu M, Deliverski T, De Marchi PRM, de The Bustamante Valles F, Ding Z, Doganov B, Dreosti L, Duarte R, Edusma-Dy R, Emelyanov S, Erman M, Fan Y, Fein L, Feng J, Fenton D, Fernandes G, Ferreira C, Franke FA, Freitas H, Fujisaka Y, Galindo H, Galvez C, Ganea D, Gil N, Girotto G, Goker E, Goksel T, Gomez Aubin G, Gomez Wolff L, Griph H, Gumus M, Hall J, Hart G, Havel L, He J, He Y, Hernandez Hernandez C, Hespanhol V, Hirashima T, Ho CMJ, Horiike A, Hosomi Y, Hotta K, Hou M, How SH, Hsia T-C, Hu Y, Ichiki M, Imamura F, Ivashchuk O, Iwamoto Y, Jaal J, Jassem J, Jordaan C, Juergens RA, Kaen D, Kalinka-Warzocha E, Karaseva N, Karaszewska B, Kazarnowicz A, Kasahara K, Katakami N, Kato T, Kawaguchi T, Kim JH, Kishi K, Kolek V, Koleva M, Kolman P, Koubkova L, Kowalyszyn R, Kowalski D, Koynov K, Ksienski D, Kubota K, Kudaba I, Kurata T, Kuusk G, Kuzina L, Laczo I, Ladrera GEI, Laktionov K, Landers G, Lazarev S, Lerzo G, Lesniewski Kmak K, Li W, Liam CK, Lifirenko I, Lipatov O, Liu X, Liu Z, Lo SH, Lopes V, Lopez K, Lu S, Martinengo G, Mas L, Matrosova M, Micheva R, Milanova Z, Miron L, Mok T, Molina M, Murakami S, Nakahara Y, Nguyen TQ, Nishimura T, Ochsenbein A, Ohira T, Ohman R, Ong CK, Ostoros G, Ouyang X, Ovchinnikova E, Ozyilkan O, Petruzelka L, Pham XD, Picon P, Piko B, Poltoratsky A, Ponomarova O, Popelkova P, Purkalne G, Qin S, Ramlau R, Rappaport B, Rey F, Richardet E, Roubec J, Ruff P, Rusyn A, Saka H, Salas J, Sandoval M, Santos L, Sawa T, Seetalarom K, Seker M, Seki N, Seolwane F, Shepherd L, Shevnya S, Shimada AK, Shparyk Y, Sinielnikov I, Sirbu D, Smaletz O, Soares JPH, Sookprasert A, Speranza G, Srimuninnimit V, Sriuranpong V, Stara Z, Su W-C, Sugawara S, Szpak W, Takahashi K, Takigawa N, Tanaka H, Tan Chun Bing J, Tang Q, Taranov P, Tejada H, Tho LM, Torii Y, Trukhyn D, Turdean M, Turna H, Ursol G, Vanasek J, Varela M, Vallejo M, Vera L, Victorino A-P, Vlasek T, Vynnychenko I, Wang B, Wang J, Wang K, Wu Y, Yamada K, Yang C-H, Yokoyama T, Yokoyama T, Yoshioka H, Yumuk F, Zambrano A, Zarba JJ, Zarubenkov O, Zemaitis M, Zhang L, Zhang L, Zhang X, Zhao J, Zhou C, Zhou J, Zhou Q, Zippelius A (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 393:1819-1830 Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, Adamchuk G, Ahn M-J, Alexandru A, Altundag O, Alyasova A, Andrusenko O, Aoe K, Araujo A, Aren O, Arrieta Rodriguez O, Ativitavas T, Avendano O, Barata F, Barrios CH, Beato C, Bergstrom P, Betticher D, Bolotina L, Bondarenko I, Botha M, Buddu S, Caglevic C, Cardona A, Castro G, Castro H, Cay Senler F, Cerny CAS, Cesas A, Chan G-C, Chang J, Chen G, Chen X, Cheng S, Cheng Y, Cherciu N, Chiu C-H, Cho BC, Cicenas S, Ciurescu D, Cohen G, Costa MA, Danchaivijitr P, De Angelis F, de Azevedo SJ, Dediu M, Deliverski T, De Marchi PRM, de The Bustamante Valles F, Ding Z, Doganov B, Dreosti L, Duarte R, Edusma-Dy R, Emelyanov S, Erman M, Fan Y, Fein L, Feng J, Fenton D, Fernandes G, Ferreira C, Franke FA, Freitas H, Fujisaka Y, Galindo H, Galvez C, Ganea D, Gil N, Girotto G, Goker E, Goksel T, Gomez Aubin G, Gomez Wolff L, Griph H, Gumus M, Hall J, Hart G, Havel L, He J, He Y, Hernandez Hernandez C, Hespanhol V, Hirashima T, Ho CMJ, Horiike A, Hosomi Y, Hotta K, Hou M, How SH, Hsia T-C, Hu Y, Ichiki M, Imamura F, Ivashchuk O, Iwamoto Y, Jaal J, Jassem J, Jordaan C, Juergens RA, Kaen D, Kalinka-Warzocha E, Karaseva N, Karaszewska B, Kazarnowicz A, Kasahara K, Katakami N, Kato T, Kawaguchi T, Kim JH, Kishi K, Kolek V, Koleva M, Kolman P, Koubkova L, Kowalyszyn R, Kowalski D, Koynov K, Ksienski D, Kubota K, Kudaba I, Kurata T, Kuusk G, Kuzina L, Laczo I, Ladrera GEI, Laktionov K, Landers G, Lazarev S, Lerzo G, Lesniewski Kmak K, Li W, Liam CK, Lifirenko I, Lipatov O, Liu X, Liu Z, Lo SH, Lopes V, Lopez K, Lu S, Martinengo G, Mas L, Matrosova M, Micheva R, Milanova Z, Miron L, Mok T, Molina M, Murakami S, Nakahara Y, Nguyen TQ, Nishimura T, Ochsenbein A, Ohira T, Ohman R, Ong CK, Ostoros G, Ouyang X, Ovchinnikova E, Ozyilkan O, Petruzelka L, Pham XD, Picon P, Piko B, Poltoratsky A, Ponomarova O, Popelkova P, Purkalne G, Qin S, Ramlau R, Rappaport B, Rey F, Richardet E, Roubec J, Ruff P, Rusyn A, Saka H, Salas J, Sandoval M, Santos L, Sawa T, Seetalarom K, Seker M, Seki N, Seolwane F, Shepherd L, Shevnya S, Shimada AK, Shparyk Y, Sinielnikov I, Sirbu D, Smaletz O, Soares JPH, Sookprasert A, Speranza G, Srimuninnimit V, Sriuranpong V, Stara Z, Su W-C, Sugawara S, Szpak W, Takahashi K, Takigawa N, Tanaka H, Tan Chun Bing J, Tang Q, Taranov P, Tejada H, Tho LM, Torii Y, Trukhyn D, Turdean M, Turna H, Ursol G, Vanasek J, Varela M, Vallejo M, Vera L, Victorino A-P, Vlasek T, Vynnychenko I, Wang B, Wang J, Wang K, Wu Y, Yamada K, Yang C-H, Yokoyama T, Yokoyama T, Yoshioka H, Yumuk F, Zambrano A, Zarba JJ, Zarubenkov O, Zemaitis M, Zhang L, Zhang L, Zhang X, Zhao J, Zhou C, Zhou J, Zhou Q, Zippelius A (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 393:1819-1830

go back to reference Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef

go back to reference Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 389:255–265CrossRef Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 389:255–265CrossRef

go back to reference Santambrogio L, Rammensee HG (2019) Contribution of the plasma and lymph degradome and peptidome to the MHC ligandome. Immunogenetics 71:203–216CrossRef Santambrogio L, Rammensee HG (2019) Contribution of the plasma and lymph degradome and peptidome to the MHC ligandome. Immunogenetics 71:203–216CrossRef

go back to reference Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30:839–844CrossRef Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30:839–844CrossRef

go back to reference Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, Group IMS (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378:2288-2301 Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, Group IMS (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378:2288-2301